Evropska unija - latvijščina - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazona hidrohlorīds - cukura diabēts, 2. tips - cukura diabēts - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. pēc tam, kad sākta terapija ar pioglitazone, pacientiem būtu jāpārskata pēc 3 līdz 6 mēnešiem, lai novērtētu atbilstību ārstēšanas e. samazinājums hba1c). pacientiem, kas nespēj izrādīt pienācīgu atbildi, pioglitazone būtu jāpārtrauc. Ņemot vērā potenciālos riskus, ar ilgstošu terapiju, prescribers jāapstiprina turpmāk kārtējās atsauksmes, ka labā pioglitazone ir saglabāta (skatīt 4. iedaļu.

Latvija - latvijščina - Zāļu valsts aģentūra

teva b.v., netherlands - mikofenolskābe - zarnās šķīstošās tabletes - 360 mg

Latvija - latvijščina - Zāļu valsts aģentūra

teva b.v., netherlands - mikofenolskābe - zarnās šķīstošās tabletes - 180 mg

Evropska unija - latvijščina - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - oftalmoloģiskie līdzekļi - beovu ir norādīts ārstēšanai pieaugušajiem neovascular (wet) vecuma saistīto makulas deģenerāciju (amd).

Evropska unija - latvijščina - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Evropska unija - latvijščina - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - oftalmoloģiskie līdzekļi - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Evropska unija - latvijščina - EMA (European Medicines Agency)

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Evropska unija - latvijščina - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - krūts audzējs - antineoplastiski līdzekļi - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Latvija - latvijščina - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - febuksostats - apvalkotā tablete - 80 mg

Latvija - latvijščina - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - febuksostats - apvalkotā tablete - 120 mg